Ernexa Therapeutics Inc. Interest Expense Operating
Ernexa Therapeutics Inc. (ERNA) reported Interest Expense Operating of $1.40 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-12.
Financial Statements › Expense Statement › Interest Expense
us-gaap:InterestExpenseOperating · last filed 2025-03-12
- Ernexa Therapeutics Inc. interest expense operating for fiscal 2024 was $1.40M, a 366.67% increase from fiscal 2023.
- Ernexa Therapeutics Inc. interest expense operating for fiscal 2023 was $300.00K.
| Period end | Interest Expense Operating 12 month |
|---|---|
| 2024-12-31 | $1.40M 10-K · filed 2025-03-12 |
| 2023-12-31 | $300.00K 10-K · filed 2025-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |